Dong Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dong Yang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hai-Liang Zhang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
10 shared publications - Jia-Hong Tang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
10 shared publications - Jia-Lu Shan
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
10 shared publications - Kai-Ming Zhang
Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer Guangzhou Guangdong China
10 shared publications - Rong Deng
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
10 shared publications - Tian Du
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
10 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Adjuvant sandwich therapy is associated with improved survival in stage III–IVA endometrial cancer: a network meta-analysis
Chen X, et al. J Gynecol Oncol. 2026 ;37:e100. https://doi.org/10.3802/jgo.2026.37.e100
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Open AccessAdjuvant sandwich therapy is associated with improved survival in stage III–IVA endometrial cancer: a network meta-analysis
Chen X, et al. J Gynecol Oncol. 2026 ;37:e100. https://doi.org/10.3802/jgo.2026.37.e100
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in Flow cytometry analysis
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in Flow cytometry analysis
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S2. Targeting mutant NRAS activates the STING signaling. A-B. The indicated NRAS mutant cells and wild type NRAS cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (A) and qRT-PCR analysis (n = 3 biological independent samples) (B). C-D. The indicated NRAS wild type cells A2058, A375 were transiently transfected with site-specific siRNAs targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples) (C) and western blot analysis (D). E. The schematic overview of RNA-seq in HT1080 cell lines. F-G. HT1080, ME4405, SNU719 cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (F) and qRT-PCR analysis (n = 3 biological independent samples) (G). H. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). I. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were treated with 200ng/mL poly(dA:dT) for 18h. The cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). Error bars represent mean ± SD. The p-values in B and G were determined by a two-tailed unpaired Student’s t test.The p-values in C and H-I were calculated using one-way ANOVA followed by Dunnett's multiple comparisons test, **p < 0.01. Data in A-D, F-G are representative of three independent experiments. Data in H-I are representative of two independent experiments.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S2. Targeting mutant NRAS activates the STING signaling. A-B. The indicated NRAS mutant cells and wild type NRAS cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (A) and qRT-PCR analysis (n = 3 biological independent samples) (B). C-D. The indicated NRAS wild type cells A2058, A375 were transiently transfected with site-specific siRNAs targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples) (C) and western blot analysis (D). E. The schematic overview of RNA-seq in HT1080 cell lines. F-G. HT1080, ME4405, SNU719 cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (F) and qRT-PCR analysis (n = 3 biological independent samples) (G). H. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). I. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were treated with 200ng/mL poly(dA:dT) for 18h. The cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). Error bars represent mean ± SD. The p-values in B and G were determined by a two-tailed unpaired Student’s t test.The p-values in C and H-I were calculated using one-way ANOVA followed by Dunnett's multiple comparisons test, **p < 0.01. Data in A-D, F-G are representative of three independent experiments. Data in H-I are representative of two independent experiments.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S1 The clinical significance of the interferon alpha response in NRAS wild-type melanoma patients in the TCGA cohort. Kaplan-Meier analyses of OS, DSS and PFS based on enrichment score of the interferon alpha response for patients with NRAS wild-type melanoma. The data were retrieved from TCGA database.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S1 The clinical significance of the interferon alpha response in NRAS wild-type melanoma patients in the TCGA cohort. Kaplan-Meier analyses of OS, DSS and PFS based on enrichment score of the interferon alpha response for patients with NRAS wild-type melanoma. The data were retrieved from TCGA database.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
The source data related to this study are provided in the Supplementary Source Data file.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
The source data related to this study are provided in the Supplementary Source Data file.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in immunoblot and immunoprecipitation
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in immunoblot and immunoprecipitation
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Clinical characteristics of melanoma patients in TCGA
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Clinical characteristics of melanoma patients in TCGA
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S3. The suppression of cGAS-STING pathway in NRAS mutant cells mediates immune escape. A. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with poly(dA:dT). B. Immunoblot in NCI-H1299 cells expressing sgRNA targeting STING. C. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with HT-DNA. D-E. Flow cytometry measuring the cytotoxicity of PBMCs that killing the cancer cells pre-treated with poly(dA:dT) (D) and HT-DNA(E). F. FACS analysis of CD8+T, NK1.1+, and IFNγ+ or Granzyme B+ in CD8+ T cell populations and NK cell populations from the isolated TILs. Representative dot plots from a representative mouse for each group.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S3. The suppression of cGAS-STING pathway in NRAS mutant cells mediates immune escape. A. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with poly(dA:dT). B. Immunoblot in NCI-H1299 cells expressing sgRNA targeting STING. C. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with HT-DNA. D-E. Flow cytometry measuring the cytotoxicity of PBMCs that killing the cancer cells pre-treated with poly(dA:dT) (D) and HT-DNA(E). F. FACS analysis of CD8+T, NK1.1+, and IFNγ+ or Granzyme B+ in CD8+ T cell populations and NK cell populations from the isolated TILs. Representative dot plots from a representative mouse for each group.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
NRAS is commonly mutated in several different types of human cancer. NRAS-mutant tumors are aggressive and associated with poor outcomes. Although the development of targeted therapies as well as immune checkpoint inhibitors has led to a substantial improvement in the overall survival of patients with NRAS wild-type (WT) tumors, current therapies for NRAS-mutant cancers are limited. In this study, analysis of RNA sequencing data revealed a downregulation of the type I IFN response in NRAS-mutant tumors compared with NRAS WT tumors, which was associated with poor prognosis in NRAS-mutant melanoma. Knockdown of mutant NRAS, but not WT NRAS, enhanced the activation of cyclic GMP-AMP synthase (cGAS)–STING signaling. The formation of a trimeric complex between TBK1, STING, and IFN regulatory factor 3, which is required for the activation and nuclear translocation, was blocked in NRAS-mutant tumor cells. Inactivation of innate immune signaling by mutant NRAS altered cytokine production, resulting in cell autonomous and non–cell autonomous signaling to prevent tumor cell death and in evasion of tumor-immune surveillance. Screening of drugs for the ability to stimulate the release of CXCL10 revealed that SOS1 inhibitors reactivated cGAS–STING signaling in NRAS-mutant tumor cells. Importantly, combining SOS1 inhibitors with STING agonists maximized the activation of cGAS–STING signaling and elicited an increased antitumor immune response in vitro and in vivo. Overall, this study provides insights into the regulation of antitumor immunity by mutant NRAS and uncovers a potential strategy for treating NRAS-mutant cancer.Significance:Suppression of innate immune signaling in NRAS-mutant tumors results from downregulation of the cGAS–STING axis and can be reversed using SOS1 inhibitors combined with STING agonists to restrain NRAS-mutant tumor growth.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
NRAS is commonly mutated in several different types of human cancer. NRAS-mutant tumors are aggressive and associated with poor outcomes. Although the development of targeted therapies as well as immune checkpoint inhibitors has led to a substantial improvement in the overall survival of patients with NRAS wild-type (WT) tumors, current therapies for NRAS-mutant cancers are limited. In this study, analysis of RNA sequencing data revealed a downregulation of the type I IFN response in NRAS-mutant tumors compared with NRAS WT tumors, which was associated with poor prognosis in NRAS-mutant melanoma. Knockdown of mutant NRAS, but not WT NRAS, enhanced the activation of cyclic GMP-AMP synthase (cGAS)–STING signaling. The formation of a trimeric complex between TBK1, STING, and IFN regulatory factor 3, which is required for the activation and nuclear translocation, was blocked in NRAS-mutant tumor cells. Inactivation of innate immune signaling by mutant NRAS altered cytokine production, resulting in cell autonomous and non–cell autonomous signaling to prevent tumor cell death and in evasion of tumor-immune surveillance. Screening of drugs for the ability to stimulate the release of CXCL10 revealed that SOS1 inhibitors reactivated cGAS–STING signaling in NRAS-mutant tumor cells. Importantly, combining SOS1 inhibitors with STING agonists maximized the activation of cGAS–STING signaling and elicited an increased antitumor immune response in vitro and in vivo. Overall, this study provides insights into the regulation of antitumor immunity by mutant NRAS and uncovers a potential strategy for treating NRAS-mutant cancer.Significance:Suppression of innate immune signaling in NRAS-mutant tumors results from downregulation of the cGAS–STING axis and can be reversed using SOS1 inhibitors combined with STING agonists to restrain NRAS-mutant tumor growth.